Friday 6 November 2026 Export CLGN’s income statement to Excel — free account

CollPlant Biotechnologies Ltd. Sponsored ADR

CollPlant Biotechnologies Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, up 360.4% from fiscal 2024.

Revenue: −39.7%
EPS: +32.5%
Free cash flow: +5.08%

Quarter to June 2026, against a year earlier

3.85 0.09 −2.28%

Follow CLGN

Alert me

Market cap: $7.5M
P/E: 0.0×
Fwd P/E: −0.7×
Dividend yield: —
F-score: 4/9
Altman Z: −16.87
Beneish M: −3.20
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Size

Market Cap 7.45

Revenue ttm 0.32

Net income ttm (12.51)

Free cash flow ttm (11.20)

Net debt Q (2.95)

Valuation

P/E 0.00

Forward P/E (0.71)

Price / sales 18.24

Forward P/S Powerpack

Price / FCF 0.00

Price / book 1.97

Financial health

Current ratio Q 1.57

Debt / equity Q 0.00

Interest coverage Q (28.31)

Growth

Revenue growth Q −39.66%

Operating income growth Q +17.15%

EPS, this year +35.10%

EPS, next year A +69.24%

Revenue, next year A +157.57%

EPS, past 5 yrs —

EPS, next 5 yrs A +43.71%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 56.69%

10-year low 10-year high

P/B against its own 10 years 15.11%

10-year low 10-year high

EV/Sales against its own 10 years 64.58%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	27	12	6	3
Receivables	0	1	0	0
Inventory	1	0	1	1
Other	—	—	—	—
	28	13	7	4

	2023	2024	2025	Q'26
Payables	1	1	1	0
ST’ Debt	—	—	—	—
Other	—	—	—	—
	3	3	3	2

Compound Annual Growth %

	10y	5y	3y
Sales	—	(17.32%)	99.41%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	6.32%	(42.68%)

Earnings Trends EPS, adjusted, against the consensus

Sep 2025 Estimate 3.80 Actual −2.70

−5.40 −2.80 −0.20 2.40 5.00

Sep 2024 Miss −0.10

Dec 2024 Beat +0.80

Mar 2025 Beat +2.40

Sep 2025 Miss −6.50

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Sep 2024	−3.70	−3.80	Miss by 0.10
Dec 2024	−4.20	−3.40	Beat by 0.80
Mar 2025	−3.70	−1.30	Beat by 2.40
Sep 2025	3.80	−2.70	Miss by 6.50

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(2.30)	(1.89)	—	—	—
’25	(1.30)	(2.80)	(2.70)	(2.58)	(9.40)
’24	(3.70)	(3.70)	(3.80)	(3.40)	(14.50)
’23	(3.30)	4.90	(3.80)	(4.20)	(6.20)
’22	(3.60)	(3.90)	(4.00)	(3.90)	(15.30)
’21	8.80	(3.00)	(2.90)	(3.00)	0.20
’20	(2.40)	(2.80)	0.70	(4.20)	(8.40)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	2	0	0	0	2
’24	0	0	0	0	1
’23	0	10	0	0	11
’22	0	0	0	0	0
’21	15	1	0	0	16
’20	1	1	4	1	6

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(2)	—	—	—
’25	(1)	(2)	(3)	(3)	(9)
’24	(3)	(4)	(3)	(3)	(14)
’23	(3)	(4)	7	(2)	(3)
’22	(3)	(4)	(3)	(3)	(14)
’21	11	(3)	(3)	(2)	3
’20	(3)	(2)	1	(2)	(4)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(2)	—	—	—
’25	(1)	(2)	(3)	(3)	(9)
’24	(3)	(4)	(4)	(4)	(15)
’23	(4)	(4)	7	(3)	(4)
’22	(4)	(4)	(4)	(4)	(15)
’21	11	(4)	(3)	(3)	1
’20	(3)	(2)	1	(2)	(5)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	0	0	5	2	6	16	0	11	1	2	0		+45.1%	6	8	9	+56.9%
	Gross margin, %	100.00	96.88	66.91	18.94	51.08	87.18	(33.78)	81.83	(215.53)	64.78	(321.70)		(35.2) pt	Powerpack CollPlant Biotechnologies Ltd. Sponsored ADR’s next three years, line by line Analysts expect revenue to grow 56.9% a year to 2028 — faster than the 45.1% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(8)	(6)	(6)	(11)	(6)	0	(17)	(7)	(17)	(11)	(13)		+4.2%
	EBT margin, %	(9,522.89)	(1,251.98)	(124.63)	(481.62)	(94.09)	1.52	(5,660.54)	(64.05)	(3,225.05)	(484.56)	(3,934.91)		+9,038.3 pt
	Net income	(8)	(6)	(6)	(11)	(6)	0	(17)	(7)	(17)	(11)	(13)		+4.2%
Per share, $
Per share, $	Revenue	0.41	1.81	11.43	4.65	8.91	15.69	0.27	9.62	0.45	1.94	0.22		+18.8%
	Earnings	(39.27)	(22.60)	(14.25)	(22.40)	(8.40)	0.24	(15.30)	(6.20)	(14.50)	(9.40)	(9.47)		(14.7%)
	Cash flow	(27.26)	(19.36)	(2.78)	(11.44)	(6.46)	2.51	(12.42)	(2.43)	(12.30)	(7.72)	(7.76)		(13.1%)
	Capex	(0.69)	(0.48)	(1.90)	(2.93)	(0.75)	(1.56)	(1.19)	(0.78)	(0.42)	(0.02)	(0.01)		(31.8%)
	Free cash flow	(27.95)	(19.85)	(4.67)	(14.37)	(7.22)	0.95	(13.61)	(3.20)	(12.72)	(7.74)	(7.76)		(13.3%)
	Book value	7.26	9.84	12.36	8.20	6.50	45.26	29.26	24.88	11.76	4.98	2.04		(4.1%)
	Shares, m	0	0	0	0	1	1	1	1	1	1	1		+22.2%
Valuation, ×
Valuation, ×	P/E	2.99	8.91	0.00	0.00	0.00	74.36	0.00	0.00	0.00	0.00	0.00		8.6
	P/S	0.00	55.06	3.67	12.26	12.09	10.43	317.34	6.29	80.07	7.21	18.24		50.4
	P/B	8.74	9.96	3.40	6.95	16.57	3.61	2.94	2.43	3.06	2.81	1.97		6.0
	EV/Sales	0.00	51.95	2.58	12.98	12.43	8.01	236.33	4.33	67.05	7.00	26.12		40.3
	EV/FCF	0.00	0.00	(6.32)	(4.20)	(15.61)	132.52	(4.71)	(12.85)	(2.36)	(1.75)	(0.74)		8.5
Cash, $m
Cash, $m	Operating cash flow	(5)	(5)	(1)	(6)	(4)	3	(14)	(3)	(14)	(9)	(11)		+6.2%
	Capex	0	0	(1)	(1)	(1)	(2)	(1)	(1)	0	0	0		(16.6%)
	Free cash flow	(6)	(5)	(2)	(7)	(5)	1	(15)	(4)	(15)	(9)	(11)		+5.9%
Balance, $m
Balance, $m	Working capital	0	5	5	2	2	42	29	25	10	4	1		+31.1%
	Net debt	(1)	(1)	(5)	(4)	(3)	(43)	(30)	(27)	(12)	(6)	(3)		+22.0%
	Shareholders’ equity	1	3	5	4	4	45	32	28	13	6	3		+17.2%
Returns, %
Returns, %	ROA	(129.91)	(98.89)	(74.21)	(114.48)	(53.48)	0.76	(38.04)	(19.53)	(62.87)	(77.90)	(101.59)		+52.0 pt
	ROIC	(1,044.57)	(326.75)	0.00	(1,543.49)	(309.13)	2.25	(410.20)	(329.47)	(824.30)	(5,478.53)	0.00		(4,434.0) pt
	ROE	(387.61)	(294.98)	(155.43)	(234.83)	(134.83)	0.96	(43.73)	(23.16)	(79.46)	(117.56)	(161.98)		+270.1 pt
People
People	Employees	27	29	40	46	52	66	73	75	57	39	—		+4.2%
	Revenue/emp, $m	0.00	0.02	0.13	0.05	0.12	0.24	0.00	0.15	0.01	0.06	—		+39.3%

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 2 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LEXX Lexaria Bioscience Corp.	$8.8M	— (loss-making)	— (loss-making)	−89.12% (below 0%: shrinking)	n/m	+53.90% (above 0%: growing)	100.00%	0.00%	Compare
TOVX Theriva Biologics, Inc.	$7.7M	— (loss-making)	—	+33.08% (above 0%: growing)	n/m	+34.69% (above 0%: growing)	100.00%	0.00%	Compare
TCRT Alaunos Therapeutics, Inc.	$7.6M	— (loss-making)	— (loss-making)	+200.00% (above 0%: growing)	n/m	+57.20% (above 0%: growing)	100.00%	0.00%	Compare
ALZN Alzamend Neuro, Inc.	$7.5M	— (loss-making)	—	—	n/m	+51.82% (above 0%: growing)	0.00%	0.00%	Compare
CLGN CollPlant Biotechnologies Ltd. Sponsored ADR	$7.5M	— (loss-making)	— (loss-making)	−39.66% (below 0%: shrinking)	n/m	+5.08% (above 0%: growing)	(422.22%)	(2,437.96%)
VTGN VistaGen Therapeutics, Inc.	$7.3M	— (loss-making)	— (loss-making)	+504.92% (above 0%: growing)	n/m	+22.23% (above 0%: growing)	100.00%	(904.34%)	Compare
SNGX Soligenix Inc.	$7.3M	— (loss-making)	— (loss-making)	−98.89% (below 0%: shrinking)	n/m	+37.83% (above 0%: growing)	0.00%	0.00%	Compare
KPRX Kiora Pharmaceuticals, Inc.	$6.6M	— (loss-making)	— (loss-making)	−93.64% (below 0%: shrinking)	n/m	+50.06% (above 0%: growing)	100.00%	0.00%	Compare
CRIS Curis, Inc.	$5.7M	— (loss-making)	— (loss-making)	−65.98% (below 0%: shrinking)	n/m	−20.44% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$7.4M	—	—	−65.98%	—	+43.95%	100.00%	0.00%

All 621 Biotechnology stocks →

CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) Latest News

5 Nov

Impact 3 · 8:00 AM · GlobeNewswire

LightSolver Secures ~$1.8 Million Grant from Israel’s Innovation Authority to Advance its Laser Processing Unit (LPU)

29 Oct

Impact 4 · 8:00 AM · GlobeNewswire

LightSolver Secures Paid Collaboration with the Israel Ministry of Defense for the Development of Photonic Computing Technology

9 Oct

Impact 3 · 9:00 AM · PR Newswire

COLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENT

6 Oct

Impact 3 · 7:00 AM · PR Newswire

LightSolver Files U.S. Provisional Patent Application Expanding its Photonic Computing Platform to Advanced Scientific and Engineering Simulations

30 Sep

Impact 4 · 5:20 PM · PR Newswire

COLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Impact 4 · 7:00 AM · PR Newswire

CollPlant Biotechnologies Announces Positive Results from non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler

24 Sep

Impact 3 · 8:00 AM · PR Newswire

LightSolver, a CollPlant Company, and HLRS Joint Research Demonstrated Photonic Computing Can significantly Accelerate Fundamental HPC Workloads

22 Sep

Impact 3 · 7:30 AM · PR Newswire

CollPlant Regains Compliance with Nasdaq Minimum Bid Price Requirement

3 Sep

Impact 5 · 8:00 AM

COLLPLANT COMPLETES ACQUISITION OF LIGHTSOLVER, ENTERING THE PHOTONIC COMPUTING SECTOR

31 Aug

Impact 5 · 8:00 AM

COLLPLANT IS ACQUIRING LIGHTSOLVER- ENTERS SUPERCOMPUTING AND PHOTONIC COMPUTING MARKETS

13 Apr

Impact 3 · 7:00 AM · PR Newswire

CollPlant Issues Letter to Shareholders

26 Mar

Impact 4 · 8:30 AM · PR Newswire

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

24 Mar

Impact 4 · 4:01 PM · PR Newswire

CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement

26 Feb

Impact 3 · 8:00 AM · PR Newswire

CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler

23 Feb

Impact 4 · 7:00 AM · PR Newswire

CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex

17 Feb

Impact 4 · 7:00 AM · PR Newswire

CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments

8 Feb

Impact 3 · 7:45 AM · Simply Wall St.

When Will CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Turn A Profit?

26 Nov

Impact 3 · 7:30 AM · PR Newswire

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

13 Nov

Impact 3 · 5:13 AM · Simply Wall St.

Here's Why We're A Bit Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

27 Oct

Impact 4 · 7:00 AM

CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada

20 Oct

Impact 4 · 7:00 AM · PR Newswire

CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology

16 Oct

Impact 4 · 7:00 AM · PR NewswireInsider MonkeyInsider MonkeyMT NewswiresBusiness Wire VideosWWDLifeMinute.TV Videos

First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk

3 Oct

Impact 3 · 6:47 AM · Simply Wall St.

One CollPlant Biotechnologies Insider Raised Their Stake In The Previous Year

15 Sep

Impact 4 · 7:00 AM · PR Newswire

CollPlant Expands the Distribution of its VergenixSTR Product in Europe

2 Sep

Impact 3 · 7:00 AM

CollPlant to Present at the 2025 International Conference on Biofabrication

20 Aug

Impact 3 · 7:00 AM

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

14 Jul

Impact 4 · 7:00 AM

CollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial Operations

9 Jun

Impact 4 · 7:00 AM · PR Newswire

COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES

4 Jun

Impact 4 · 7:00 AM · PR Newswire

COLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-BASED FORMULATIONS USABLE AS SOFT TISSUE FILLERS AND IMPLANTS

30 May

Impact 3 · 8:05 AM · Simply Wall St.

Discover May 2025's Top Penny Stocks

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

CollPlant Biotechnologies Ltd. Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier

CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) Latest News

5 Nov

29 Oct

9 Oct

6 Oct

30 Sep

24 Sep

22 Sep

3 Sep

31 Aug

13 Apr

26 Mar

24 Mar

26 Feb

23 Feb

17 Feb

8 Feb

26 Nov

13 Nov

27 Oct

20 Oct

16 Oct

3 Oct

15 Sep

2 Sep

20 Aug

14 Jul

9 Jun

4 Jun

30 May

Stockrow Weekly